PE-22-28

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Bipolar disorder (any phase): TREK-1 antagonism increases neuronal excitability and monoaminergic tone; in subjects with bipolar disorder, this mechanism can trigger manic switch: the same class risk that makes antidepressant monotherapy hazardous in bipolar; absolute contraindication without mood stabilizer coverage and clinical supervision.
• Active manic or hypomanic episode: TREK-1 blockade-driven neuronal disinhibition would directly accelerate the hyperexcitable, elevated monoamine state of mania.
• Known hypersensitivity to PE-22-28, spadin-derived peptides, or formulation excipients.
• Concurrent use with MAO inhibitors: TREK-1 antagonism increases serotonin and norepinephrine availability by disinhibiting raphe and locus coeruleus neurons; combined with MAO inhibition this produces dangerous monoamine excess; serotonin syndrome risk.
• Concurrent use with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, linezolid): additive serotonergic activity; monitor for serotonin syndrome symptoms (hyperthermia, clonus, agitation, diaphoresis).
• Severe cardiovascular disease with arrhythmia: TREK-1 is expressed in cardiac tissue where it contributes to action potential repolarization; blockade of cardiac TREK-1 could affect cardiac rhythm at high doses.
• Pregnancy: no safety data; neuronal excitability modulation during fetal brain development is not established as safe.
• Breastfeeding: no safety data.
• Pediatric use: TREK-1 plays developmental roles in the maturing CNS; PE-22-28 use in pediatric subjects is not established as safe.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Overstimulation and nervous energy: the most dose-dependent adverse effect; TREK-1 blockade-driven neuronal disinhibition at higher doses produces a heightened CNS excitability state characterized by restlessness, racing thoughts, and inability to wind down; managed by strict morning administration and dose reduction.
• Headache: one of the most commonly reported adverse effects; neuronal excitability increase and monoamine elevation produce cerebrovascular effects that manifest as headache, particularly in the first 1-2 weeks; typically self-limiting.
• Insomnia: evening or late afternoon administration of PE-22-28 produces predictable sleep onset difficulty from the neuronal excitability and monoamine elevation effects; strict morning dosing mitigates.
• Mid-afternoon energy crash: reported in subjects using a single morning bolus dose; as PE-22-28 clears, the TREK-1 rebound may produce a brief period of fatigue; the split-dose alternative protocol (AM + early afternoon) was developed specifically to manage this.
• Mild anxiety: paradoxical given the antidepressant intent; neuronal hyperexcitability from TREK-1 blockade in anxiety-circuit neurons (amygdala, anterior cingulate) can produce anxious arousal alongside the antidepressant activity; Selank co-administration is the standard mitigation strategy.
• Nausea: uncommon; mild; reported in the first week of use.
• Injection site irritation: mild redness and soreness at the subcutaneous administration site.
• Palpitations: rare; TREK-1 is expressed in cardiac tissue; at higher doses, cardiac TREK-1 blockade may produce subjective palpitation awareness; not typically clinically significant in healthy subjects.
• No SSRI-class adverse effects: PE-22-28 does not block SERT, NET, or any reuptake transporter; it produces no sexual dysfunction, weight gain, emotional blunting, or discontinuation syndrome characteristic of SSRI/SNRI therapy.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• PubMed search: PE-22-28